CymaBay’s Stalled Seladelpar Back In Play For PBC

 
• By Joseph Haas
  
Second_Chance
CymaBay is taking a second chance on seladelpar in PBC after FDA lifted a clinical hold

More from Clinical Trials

More from R&D